GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
GeoVax Labs, a biotechnology company focused on vaccine and cancer immunotherapy development, has announced its participation in the 3rd Annual ROTH Healthcare Opportunities Conference on October 9, 2024 in New York. David Dodd, the company's Chairman & CEO, will be part of a panel discussion on innovative therapies for solid tumors at 12:30 pm ET.
The company's senior management will also be available for one-on-one meetings with registered attendees. Interested parties can arrange meetings through their ROTH representative or by contacting GeoVax directly at info@geovax.com.
This participation highlights GeoVax's commitment to advancing its research and development in the field of cancer immunotherapies and human vaccines.
GeoVax Labs, un'azienda biotecnologica specializzata nello sviluppo di vaccini e immunoterapie per il cancro, ha annunciato la sua partecipazione al 3° Annuale ROTH Healthcare Opportunities Conference il 9 ottobre 2024 a New York. David Dodd, presidente e CEO dell'azienda, parteciperà a una discussione di panel sulle terapie innovative per tumori solidi alle 12:30 ora dell'Est.
Il senior management dell'azienda sarà inoltre disponibile per incontri individuali con i partecipanti registrati. Le parti interessate possono organizzare incontri tramite il loro rappresentante ROTH o contattando direttamente GeoVax all'indirizzo info@geovax.com.
Questa partecipazione evidenzia l'impegno di GeoVax nell'avanzare la propria ricerca e sviluppo nel campo delle immunoterapie oncologiche e dei vaccini umani.
GeoVax Labs, una empresa biotecnológica centrada en el desarrollo de vacunas e inmunoterapia contra el cáncer, ha anunciado su participación en la 3ª Conferencia Anual ROTH de Oportunidades en Salud el 9 de octubre de 2024 en Nueva York. David Dodd, presidente y CEO de la empresa, formará parte de un panel de discusión sobre terapias innovadoras para tumores sólidos a las 12:30 pm ET.
La alta dirección de la empresa también estará disponible para reuniones individuales con los asistentes registrados. Las partes interesadas pueden organizar reuniones a través de su representante de ROTH o contactando directamente a GeoVax en info@geovax.com.
Esta participación destaca el compromiso de GeoVax con el avance de su investigación y desarrollo en el campo de las inmunoterapias contra el cáncer y las vacunas humanas.
GeoVax Labs는 백신 및 암 면역 요법 개발에 중점을 둔 생명공학 회사로서, 2024년 10월 9일 뉴욕에서 열리는 제3회 연례 ROTH 헬스케어 기회 컨퍼런스에 참여할 것이라고 발표했습니다. David Dodd는 회사의 회장 겸 CEO로서 고형 종양에 대한 혁신적인 요법에 대한 패널 토론에 오후 12시 30분 ET에 참여할 예정입니다.
회사의 고위 경영진은 등록된 참석자와의 일대일 회의를 위해서도 참석할 수 있습니다. 관심 있는 분들은 ROTH 대표를 통해 회의를 조정하거나 GeoVax에 직접 info@geovax.com으로 연락하여 회의를 요청할 수 있습니다.
이 참여는 암 면역 요법 및 인간 백신 분야의 연구 개발을 선도하려는 GeoVax의 의지를 강조합니다.
GeoVax Labs, une entreprise biotechnologique axée sur le développement de vaccins et d'immunothérapies contre le cancer, a annoncé sa participation à la 3ème Conférence Annuelle ROTH sur les Opportunités de Santé le 9 octobre 2024 à New York. David Dodd, le président et CEO de l'entreprise, participera à une discussion en panel sur les thérapies innovantes pour les tumeurs solides à 12h30 ET.
La direction de l'entreprise sera également disponible pour des réunions en tête-à-tête avec les participants enregistrés. Les personnes intéressées peuvent organiser des rendez-vous par l'intermédiaire de leur représentant ROTH ou en contactant GeoVax directement à info@geovax.com.
Cette participation souligne l'engagement de GeoVax à faire progresser sa recherche et son développement dans le domaine des immunothérapies contre le cancer et des vaccins humains.
GeoVax Labs, ein biotechnologisches Unternehmen, das sich auf die Entwicklung von Impfstoffen und Krebsimmuntherapien konzentriert, hat seine Teilnahme an der 3. jährlichen ROTH Healthcare Opportunities Conference am 9. Oktober 2024 in New York angekündigt. David Dodd, der Vorsitzende und CEO des Unternehmens, wird an einer Podiumsdiskussion über innovative Therapien für solide Tumore um 12:30 Uhr ET teilnehmen.
Die Unternehmensführung wird auch für Einzelgespräche mit registrierten Teilnehmern zur Verfügung stehen. Interessierte können Meetings über ihren ROTH-Vertreter oder direkt bei GeoVax unter info@geovax.com vereinbaren.
Diese Teilnahme unterstreicht GeoVax' Engagement, seine Forschung und Entwicklung im Bereich der Krebsimmuntherapien und menschlichen Impfstoffe voranzutreiben.
- None.
- None.
ATLANTA, Ga., Oct. 02, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chairman & CEO, David Dodd, will participate in a panel discussion on innovative therapies for solid tumors at the 3rd Annual ROTH Healthcare Opportunities Conference taking place on October 9, 2024 in New York, NY. Senior GeoVax management will also host one-on-one meetings with registered attendees.
| Panel Details: | |
| Title: | Innovative Therapies for Solid Tumors |
| Presenter: | David Dodd, Chairman & CEO |
| Date/Time: | October 9, 2024, 12:30 pm ET |
If you are interested in arranging a 1x1 meeting request with management, please contact your ROTH representative, or please contact the company directly at info@geovax.com.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines for many of the world’s most threatening infectious diseases and therapies for solid tumor cancers. The company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine for which GeoVax was recently awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 versus an approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. The Company has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.
| Company Contact: | Investor Relations Contact: | Media Contact: | ||
| info@geovax.com | austin.murtagh@precisionaq.com | sr@roberts-communications.com | ||
| 678-384-7220 | 212-698-8696 | 202-779-0929 | ||
FAQ
When and where is GeoVax (GOVX) participating in the ROTH Healthcare Opportunities Conference?
What panel will GeoVax's CEO be speaking on at the ROTH conference?
How can investors arrange meetings with GeoVax (GOVX) management at the ROTH conference?
What is the main focus of GeoVax Labs (GOVX) as a biotechnology company?
